Carlos Domingo, CEO of Securitize, joins Katie Greifeld and Isabelle Lee on "Bloomberg Crypto." They discuss why he believes it's a good time for Securitize to go public, including raising the profile of tokenization and raising capital for acquisitions. (Source: Bloomberg)
Carlos Domingo, CEO of Securitize, joins Katie Greifeld and Isabelle Lee on "Bloomberg Crypto." They discuss why he believes it's a good time for Securitize to go public, including raising the profile of tokenization and raising capital for acquisitions. (Source: Bloomberg)
JHVEPhoto/iStock Editorial via Getty Images Eli Lilly and Company ( LLY ) has been the strongest performing big pharma company over the last year. It's up 50% in the last year compared to Novo Nordisk A/S ( NVO ), which is down 44%. LLY has mainly outperformed because of strong GLP-1 revenue, but my opinion here is that if your main LLY bull case remains GLP-1 dominance, then you're missing the re...
JHVEPhoto/iStock Editorial via Getty Images Eli Lilly and Company ( LLY ) has been the strongest performing big pharma company over the last year. It's up 50% in the last year compared to Novo Nordisk A/S ( NVO ), which is down 44%. LLY has mainly outperformed because of strong GLP-1 revenue, but my opinion here is that if your main LLY bull case remains GLP-1 dominance, then you're missing the real underlying bull case. The numbers so far are great—$19.8 billion in Q1 revenue with ~$84 billion full-year revenue guidance, and Mounjaro is up 125% year-over-year. So we have a very strong underlying company, but the real value is being built based on the reinvestment from these strong numbers. The questions I'm going to try to answer for you here are what exactly LLY is doing with this free cash flow and what the company potentially looks like in 5+ years. Before that… a deeper look at the financials. Financials The headline numbers I touched on above are very strong, but here are the numbers I, personally, have looked at the most: Q1 2026 R&D spend came in at $3.5 billion, up 28% year-over-year, representing 18% of revenue. For context, that's more than most mid-cap pharma companies generate in total annual revenue, being spent in a single quarter on research alone. Full-year 2025 revenue was $65.2 billion, up 45% on 2024. The 2026 midpoint guidance of $83.5 billion implies another ~28% growth on top of that. We're now at a scale where those kinds of % gains add tens of billions in revenue per annum. Non-GAAP gross margin came in at 82.6% in Q1 2026. That is exceptional for a company with Lilly's manufacturing complexity and gives the business enormous cash conversion on every dollar of incremental GLP-1 revenue. Lilly has deployed that cash flow into four acquisitions in roughly 18 months: Verve Therapeutics (cardiovascular gene editing), Ascidian Therapeutics (RNA exon-editing for rare kidney disease), Scorpion Therapeutics (targeted oncology), and Morphic Therapeut...
SpaceX is on the verge of its initial public offering (IPO), and the stock's public debut is poised to make history. The stock will hit the Nasdaq exchange under the ticker symbol SPCX on June 12, and the company is aiming to raise $75 billion through stock sales that will value the company at approximately $1.77 trillion. The hotly anticipated IPO is set to be the largest in market history and se...
SpaceX is on the verge of its initial public offering (IPO), and the stock's public debut is poised to make history. The stock will hit the Nasdaq exchange under the ticker symbol SPCX on June 12, and the company is aiming to raise $75 billion through stock sales that will value the company at approximately $1.77 trillion. The hotly anticipated IPO is set to be the largest in market history and seemingly has SpaceX on track to instantly become one of the world's largest publicly traded companies. At a market capitalization of $1.77 trillion, the company will be valued at approximately 94.7 times the $18.7 billion in revenue it recorded last year. While the company has an enormously growth-dependent valuation, it also has some huge expansion opportunities ahead. Image source: Getty Images. Continue reading
Bloomberg's Emily Nicolle joins Katie Greifeld and Isabelle Lee on "Bloomberg Crypto." FTX co-founder Sam Bankman-Fried formally applied for a presidential pardon, more than two years after he was convicted over the multi-billion dollar collapse of his once-thriving cryptocurrency empire. (Source: Bloomberg)
Bloomberg's Emily Nicolle joins Katie Greifeld and Isabelle Lee on "Bloomberg Crypto." FTX co-founder Sam Bankman-Fried formally applied for a presidential pardon, more than two years after he was convicted over the multi-billion dollar collapse of his once-thriving cryptocurrency empire. (Source: Bloomberg)
Bloomberg's Emily Nicolle joins Katie Greifeld and Isabelle Lee on "Bloomberg Crypto." Bitcoin steadied itself after dropping below the key threshold of $60,000, as Strategy Chairman Michael Saylor resumed making purchases of the token. (Source: Bloomberg)
Bloomberg's Emily Nicolle joins Katie Greifeld and Isabelle Lee on "Bloomberg Crypto." Bitcoin steadied itself after dropping below the key threshold of $60,000, as Strategy Chairman Michael Saylor resumed making purchases of the token. (Source: Bloomberg)
neiu20001/iStock Editorial via Getty Images Designer Brands Inc. ( DBI ) reported the company’s fiscal Q1 results from the February-April period on the 9 th of June. The footwear retailer and brand portfolio owner showed impressive gross margin gains and good brand portfolio growth, but slow sales and a concerning EPS guidance ultimately matter more. Concerning industry trends continue to weigh on...
neiu20001/iStock Editorial via Getty Images Designer Brands Inc. ( DBI ) reported the company’s fiscal Q1 results from the February-April period on the 9 th of June. The footwear retailer and brand portfolio owner showed impressive gross margin gains and good brand portfolio growth, but slow sales and a concerning EPS guidance ultimately matter more. Concerning industry trends continue to weigh on Designer Brands alongside other footwear retailers, and macroeconomic pressure has further slowed down the sector environment. The stock is down by nearly -24% after earnings as of writing, as the report pushed back hopes of a turnaround. I maintained a Sell rating in my previous December 2025 article on the stock, titled “ Designer Brands Q3: A Clear EPS Beat, But Not Good Enough. ” The stock has since lost -5% of its value; meanwhile, the S&P 500 has gained 7%. My Rating History on DBI (Seeking Alpha) Designer Brands Q1 Review Designer Brands’ Q1 financials didn’t fall far from Wall Street’s consensus expectations for the quarter. Revenues came in less than half a million below the consensus at $696 million, whereas the quarter’s $0.07 adjusted EPS beat the consensus by four cents. Once again, sales were weak in the report, but the profitability trend was impressively strong when considering a weak sales trend. Starting with what I believe to be the report’s largest negative, despite some stabilization, Designer Brands’ retail sales performance remains very weak. Comparable sales declined by -1.1%, showing growth significantly below 2.5% to 4.2% apparel inflation for the quarter while already comparing to a very weak sales level a year ago. A near-consistent retail sales decline has continued for three years already. Declining retail store sales remain a significant long-term concern; stable sales are ultimately critical to maintaining profitability in retail. Designer Brand has closed six net stores during the past year, bringing the total to 663 after Q1. Total retail ...
Ontario Teachers' Pension Plan (OTPP) could be sitting on a paper windfall of as much as $11.6 billion from its early investment in Elon Musk-backed SpaceX as the rocket and satellite company prepares to begin trading on the Nasdaq on...
Ontario Teachers' Pension Plan (OTPP) could be sitting on a paper windfall of as much as $11.6 billion from its early investment in Elon Musk-backed SpaceX as the rocket and satellite company prepares to begin trading on the Nasdaq on...